CYP3A4 and rhabdomyolysis: In this case, replacement of treatments with appropriate alternatives, such as the use of a different statin not metabolized through the CYP3A4 pathway or changing the antihypertensive treatment regimen, can reduce the risk of serious complications such as rhabdomyolysis.